PDF(Pubmed)
Abstract：
UNASSIGNED: Centrally located hepatocellular carcinoma (HCC) typically presents challenges in surgical intervention and is associated with a bleak prognosis. In order to address this pressing issue, it is imperative to identify a comprehensive treatment approach, such as neoadjuvant radiotherapy (neoRT), that can enhance the prognosis of patients diagnosed with centrally located HCC.
UNASSIGNED: Patients who had surgical resections for HCC between March 2015 and December 2020 were included in the study. Patients were assigned to either the neoRT combined with liver resection (neoRT+LR) group or the liver resection alone (LR) group. The study employed propensity-score analysis and Cox proportional-hazards regression models as research methodologies. Using the Kaplan-Meier method, overall survival (OS) and disease-free survival (DFS) were estimated in patients.
UNASSIGNED: During the study, 162 patients were enrolled, with 41 receiving neoRT+LR and 121 receiving LR. The duration of the median follow-up period was 45 months. The 1-year, 3-year, and 5-year OS rates were 95, 70, and 70% for patients in the neoRT+LR group, and 82, 64, and 54% for patients in the LR group, respectively. The 1-year, 3-year, 5-year DFS rates were 71, 53, and 37% for patients in the neoRT+LR group, and 52, 38, and 34% for patients in the LR group, respectively. A successful matching of 37 patients was achieved through propensity-score analysis. OS and DFS after matching analysis was statistically different between the two groups ( P=0.0099, P=0.034, respectively). neoRT was an independent prognostic factor for OS and DFS [hazard ratio (HR)=0.47, 95% CI: 0.24-0.93; HR=0.56, 95% CI: 0.34-0.92, respectively]. According to matching analysis, there were no statistically significant differences observed in terms of baseline characteristics, surgical safety, and complications between the groups.
UNASSIGNED: Liver resection and neoRT can be advantageous for patients with centrally located HCC.
UNASSIGNED: Patients who had surgical resections for HCC between March 2015 and December 2020 were included in the study. Patients were assigned to either the neoRT combined with liver resection (neoRT+LR) group or the liver resection alone (LR) group. The study employed propensity-score analysis and Cox proportional-hazards regression models as research methodologies. Using the Kaplan-Meier method, overall survival (OS) and disease-free survival (DFS) were estimated in patients.
UNASSIGNED: During the study, 162 patients were enrolled, with 41 receiving neoRT+LR and 121 receiving LR. The duration of the median follow-up period was 45 months. The 1-year, 3-year, and 5-year OS rates were 95, 70, and 70% for patients in the neoRT+LR group, and 82, 64, and 54% for patients in the LR group, respectively. The 1-year, 3-year, 5-year DFS rates were 71, 53, and 37% for patients in the neoRT+LR group, and 52, 38, and 34% for patients in the LR group, respectively. A successful matching of 37 patients was achieved through propensity-score analysis. OS and DFS after matching analysis was statistically different between the two groups ( P=0.0099, P=0.034, respectively). neoRT was an independent prognostic factor for OS and DFS [hazard ratio (HR)=0.47, 95% CI: 0.24-0.93; HR=0.56, 95% CI: 0.34-0.92, respectively]. According to matching analysis, there were no statistically significant differences observed in terms of baseline characteristics, surgical safety, and complications between the groups.
UNASSIGNED: Liver resection and neoRT can be advantageous for patients with centrally located HCC.
摘要：
■位于中央的肝细胞癌（HCC）通常在手术干预中面临挑战，并且与预后暗淡有关。为了解决这个紧迫的问题，必须确定一种综合的治疗方法，例如新辅助放疗（neoRT），这可以提高诊断为中央肝癌患者的预后。
■在2015年3月至2020年12月期间接受HCC手术切除的患者被纳入研究。患者被分配到neoRT联合肝切除术（neoRTLR）组或单独肝切除术（LR）组。该研究采用倾向得分分析和Cox比例风险回归模型作为研究方法。使用Kaplan-Meier方法，评估患者的总生存期(OS)和无病生存期(DFS).
■在研究期间，162名患者入选，41个接收neoRT+LR，121个接收LR。中位随访期为45个月。1年,3年,neoRT+LR组患者的5年OS率分别为95％、70％和70％，LR组的患者分别为82％、64％和54％，分别。1年,3年,neoRT+LR组患者的5年DFS率分别为71％、53％和37％，LR组的患者分别为52％、38％和34％，分别。通过倾向评分分析，成功匹配了37例患者。匹配分析后，两组的OS和DFS差异有统计学意义（P=0.0099，P=0.034）。新RT是OS和DFS的独立预后因素[风险比（HR）=0.47，95％CI：0.24-0.93;HR=0.56，95％CI：0.34-0.92，分别]。根据匹配分析,在基线特征方面没有观察到统计学上的显著差异，手术安全,以及组间的并发症。
■肝切除和新RT对于位于中央的HCC患者可能是有利的。
■在2015年3月至2020年12月期间接受HCC手术切除的患者被纳入研究。患者被分配到neoRT联合肝切除术（neoRTLR）组或单独肝切除术（LR）组。该研究采用倾向得分分析和Cox比例风险回归模型作为研究方法。使用Kaplan-Meier方法，评估患者的总生存期(OS)和无病生存期(DFS).
■在研究期间，162名患者入选，41个接收neoRT+LR，121个接收LR。中位随访期为45个月。1年,3年,neoRT+LR组患者的5年OS率分别为95％、70％和70％，LR组的患者分别为82％、64％和54％，分别。1年,3年,neoRT+LR组患者的5年DFS率分别为71％、53％和37％，LR组的患者分别为52％、38％和34％，分别。通过倾向评分分析，成功匹配了37例患者。匹配分析后，两组的OS和DFS差异有统计学意义（P=0.0099，P=0.034）。新RT是OS和DFS的独立预后因素[风险比（HR）=0.47，95％CI：0.24-0.93;HR=0.56，95％CI：0.34-0.92，分别]。根据匹配分析,在基线特征方面没有观察到统计学上的显著差异，手术安全,以及组间的并发症。
■肝切除和新RT对于位于中央的HCC患者可能是有利的。
